“…Tamiflu was discovered by Gilead Sciences in 1995, patented in 1996, co-developed with F. Hoffmann-La Roche Ltd and marketed by F. Hoffmann-La Roche and commercially launched in November 1999 [ [16] , [17] , [18] , [19] , [20] , [21] ] In the early years of its discovery, (−)-shikimic acid was used as starting material for the synthesis of Tamiflu and furthermore, the current and only industrial synthetic route still uses (−)-shikimic acid. In response to an increasing threat of an influenza pandemic, diverse synthetic approaches have been developed and very insightful reviews of their relative merits have been published [ [1] , [2] , [3] , [22] , [23] , [24] , [25] , [26] , [27] ] However, there were legitimate (−)-shikimic acid availability concerns in the early years of the development of this drug. Shikimic acid, which is a natural product isolated from a plant of Chinese star anise was unavailable in consistent purity and enough quantity, which prompted extensive studies into (−)-shikimic acid free synthetic routes in both industry and academia.…”